Calcipotriene and betamethasone dipropionate: Difference between revisions
No edit summary |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
|drugClass=combination of a [[vitamin D]] analog and a [[corticosteroid]] | |drugClass=combination of a [[vitamin D]] analog and a [[corticosteroid]] | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=plaque psoriasis in patients 18 years of age and older | |indication=[[psoriasis|plaque psoriasis]] in patients 18 years of age and older | ||
|adverseReactions=tingling of skin, burning sensation, stinging sensation, and skin rash | |adverseReactions=[[tingling of skin]], burning sensation, stinging sensation, and [[skin rash]] | ||
|blackBoxWarningTitle='''<span style="color:#FF0000;"></span>''' | |blackBoxWarningTitle='''<span style="color:#FF0000;"></span>''' | ||
|blackBoxWarningBody=''<span style="color:#FF0000;"></span>'' | |blackBoxWarningBody=''<span style="color:#FF0000;"></span>'' | ||
|fdaLIADAdult= | |fdaLIADAdult=[[Calcipotriene]] and [[betamethasone dipropionate]] is indicated for the topical treatment of [[psoriasis|plaque psoriasis]] in patients 18 years of age and older. | ||
'''Dosing Information''' | '''Dosing Information''' | ||
*Apply | *Apply [[calcipotriene]] and [[betamethasone dipropionate]] to affected areas once daily for up to 4 weeks. Rub in [[calcipotriene]] and [[betamethasone dipropionate]] gently. Discontinue use when control is achieved. | ||
*Instruct patients not to use more than 60 g every 4 days. | *Instruct patients not to use more than 60 g every 4 days. | ||
|offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Calcipotriene and betamethasone dipropionate in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of [[Calcipotriene]] and [[betamethasone dipropionate]] in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Calcipotriene and betamethasone dipropionate in adult patients. | |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of [[Calcipotriene]] and [[betamethasone dipropionate]] in adult patients. | ||
|offLabelPedGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Calcipotriene and betamethasone dipropionate in pediatric patients. | |offLabelPedGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of [[Calcipotriene]] and [[betamethasone dipropionate]] in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of Calcipotriene and betamethasone dipropionate in pediatric patients. | |offLabelPedNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported Use'' of [[Calcipotriene]] and [[betamethasone dipropionate]] in pediatric patients. | ||
|warnings=*Flammability | |warnings=*Flammability | ||
**The propellants in | **The propellants in [[calcipotriene]] and [[betamethasone dipropionate]] are flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. | ||
*Hypercalcemia and Hypercalciuria | *[[Hypercalcemia]] and [[Hypercalciuria]] | ||
**Hypercalcemia and hypercalciuria have been observed with use of | **[[Hypercalcemia]] and [[hypercalciuria]] have been observed with use of [[calcipotriene]] and [[betamethasone dipropionate]]. If [[hypercalcemia]] or [[hypercalciuria]] develop, discontinue treatment until parameters of [[calcium metabolism]] have normalized. | ||
**The incidence of hypercalcemia and hypercalciuria following | **The incidence of [[hypercalcemia]] and [[hypercalciuria]] following [[calcipotriene]] and [[betamethasone dipropionate]] treatment of more than 4 weeks has not been evaluated. | ||
*Effects on Endocrine System | *Effects on [[endocrine system|Endocrine System]] | ||
**Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Factors that predispose a patient to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test. | **Systemic absorption of topical [[corticosteroids]] can produce reversible [[HPA axis|hypothalamic-pituitary-adrenal (HPA) axis]] suppression with the potential for clinical [[glucocorticosteroid]] insufficiency. This may occur during treatment or upon withdrawal of the topical [[corticosteroid]]. Factors that predispose a patient to [[HPA axis]] suppression include the use of high-potency [[steroids]], large treatment surface areas, prolonged use, use of [[occlusive dressing|occlusive dressings]], altered skin barrier, [[liver failure]], and young age. Evaluation for [[HPA axis]] suppression may be done by using the [[adrenocorticotropic hormone]] (ACTH) stimulation test. | ||
**If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. | **If [[HPA axis]] suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent [[corticosteroid]]. | ||
**Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. | **Systemic effects of topical [[corticosteroids]] may also include [[Cushing's syndrome]], [[hyperglycemia]], and [[glucosuria]]. | ||
**Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios. | **Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios. | ||
**Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure. | **Use of more than one [[corticosteroid]]-containing product at the same time may increase total systemic [[corticosteroid]] exposure. | ||
*Allergic Contact Dermatitis | *[[Allergic contact dermatitis|Allergic Contact Dermatitis]] | ||
**Allergic contact dermatitis has been observed with topical calcipotriene and topical corticosteroids. Allergic contact dermatitis to a topical corticosteroid is usually diagnosed by observing a failure to heal rather than a clinical exacerbation. Corroborate such an observation with appropriate diagnostic patch testing. | **[[Allergic contact dermatitis]] has been observed with topical [[calcipotriene]] and topical [[corticosteroids]]. [[Allergic contact dermatitis]] to a topical [[corticosteroid]] is usually diagnosed by observing a failure to heal rather than a clinical exacerbation. Corroborate such an observation with appropriate diagnostic patch testing. | ||
*Risks of Ultraviolet Light Exposures | *Risks of [[ultraviolet light|Ultraviolet Light]] Exposures | ||
**Patients who apply | **Patients who apply [[calcipotriene]] and [[betamethasone dipropionate]] to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. | ||
**Physicians may wish to limit or avoid use of phototherapy in patients who use | **Physicians may wish to limit or avoid use of [[phototherapy]] in patients who use [[calcipotriene]] and [[betamethasone dipropionate]]. | ||
|clinicalTrials=Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. | |clinicalTrials=Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. | ||
The rates of adverse reactions given below were derived from three randomized, multicenter, prospective vehicle and/or active-controlled clinical trials in subjects with plaque psoriasis. Subjects applied study product once daily for 4 weeks, and the median weekly dose of | The rates of adverse reactions given below were derived from three randomized, multicenter, prospective vehicle and/or active-controlled clinical trials in subjects with [[psoriasis|plaque psoriasis]]. Subjects applied study product once daily for 4 weeks, and the median weekly dose of [[calcipotriene]] and [[betamethasone dipropionate]] was 24.8 g. | ||
Adverse reactions reported in <1% of subjects treated with | Adverse reactions reported in <1% of subjects treated with [[calcipotriene]] and [[betamethasone dipropionate]] included: application site [[irritation]], application site [[pruritus]], [[folliculitis]], skin [[hypopigmentation]], [[hypercalcemia]], [[urticaria]], and exacerbation of [[psoriasis]]. | ||
|postmarketing=Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. | |postmarketing=Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. | ||
Postmarketing reports for local adverse reactions to topical steroids include atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection and miliaria. | Postmarketing reports for local adverse reactions to topical [[steroids]] include [[atrophy]], [[striae]], [[telangiectasia]], [[skin dryness|dryness]], [[perioral dermatitis]], [[secondary infection]] and [[miliaria]]. | ||
|FDAPregCat=C | |FDAPregCat=C | ||
|useInPregnancyFDA=There are no adequate and well-controlled studies in pregnant women. Pregnant women were excluded from the clinical studies conducted with | |useInPregnancyFDA=There are no adequate and well-controlled studies in pregnant women. Pregnant women were excluded from the clinical studies conducted with [[calcipotriene]] and [[betamethasone dipropionate]]. [[calcipotriene]] and [[betamethasone dipropionate]] should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. Animal reproduction studies have not been conducted with [[calcipotriene]] and [[betamethasone dipropionate]]. [[Calcipotriene]] and [[betamethasone dipropionate]] contains [[calcipotriene]] that has been shown to be fetotoxic and [[betamethasone dipropionate]] that has been shown to be teratogenic in animals when given systemically. | ||
Teratogenicity studies with calcipotriene were performed by the oral route in rats and rabbits. In rabbits, increased maternal and fetal toxicity were noted at a dosage of 12 mcg/kg/day (144 mcg/m2/day); a dosage of 36 mcg/kg/day (432 mcg/m2/day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (324 mcg/m2/day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles were most likely due to the effect of calcipotriene upon calcium metabolism. The estimated maternal and fetal no-adverse effect levels (NOAEL) in the rat (108 mcg/m2/day) and rabbit (48 mcg/m2/day) derived from oral studies are lower than the estimated maximum topical dose of calcipotriene in man (460 mcg/m2/day). | [[Teratogenicity]] studies with [[calcipotriene]] were performed by the oral route in rats and rabbits. In rabbits, increased maternal and fetal toxicity were noted at a dosage of 12 mcg/kg/day (144 mcg/m2/day); a dosage of 36 mcg/kg/day (432 mcg/m2/day) resulted in a significant increase in the incidence of incomplete [[ossification]] of the [[pubic bone|pubic bones]] and forelimb [[phalanges]] of fetuses. In a rat study, a dosage of 54 mcg/kg/day (324 mcg/m2/day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged [[fontanelles]] and extra [[ribs]]). The enlarged [[fontanelles]] were most likely due to the effect of [[calcipotriene]] upon [[calcium metabolism]]. The estimated maternal and fetal no-adverse effect levels (NOAEL) in the rat (108 mcg/m2/day) and rabbit (48 mcg/m2/day) derived from oral studies are lower than the estimated maximum topical dose of [[calcipotriene]] in man (460 mcg/m2/day). | ||
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. | [[Corticosteroids]] have been shown to be [[teratogenic]] in laboratory animals when administered systemically at relatively low dosage levels. | ||
Betamethasone dipropionate has been shown to be teratogenic in mice and rabbits when given by the subcutaneous route at dosages of 156 mcg/kg/day (468 mcg/m2/day) and 2.5 mcg/kg/day (30 mcg/m2/day), respectively. Those dose levels are lower than the estimated maximum topical dose in man (about 5,950 mcg/m2/day). The abnormalities observed included umbilical hernia, exencephaly and cleft palate. | [[Betamethasone dipropionate]] has been shown to be [[teratogenic]] in mice and rabbits when given by the [[subcutaneous]] route at dosages of 156 mcg/kg/day (468 mcg/m2/day) and 2.5 mcg/kg/day (30 mcg/m2/day), respectively. Those dose levels are lower than the estimated maximum topical dose in man (about 5,950 mcg/m2/day). The abnormalities observed included [[umbilical hernia]], [[exencephaly]], and [[cleft palate]]. | ||
Two oral peri- and post-natal development studies were conducted with rats: | Two oral peri- and post-natal development studies were conducted with rats: | ||
Pregnant Wistar rats were dosed daily with calcipotriene at exposures of 0, 6, 18 or 54 mcg/kg/day from gestation day 15 through day 20 postpartum. No remarkable effects were observed on any parameter, including survival, behavior, body weight, litter parameters, or the ability to nurse or rear pups | Pregnant Wistar rats were dosed daily with [[calcipotriene]] at exposures of 0, 6, 18 or 54 mcg/kg/day from gestation day 15 through day 20 postpartum. No remarkable effects were observed on any parameter, including survival, behavior, body weight, litter parameters, or the ability to nurse or rear pups. | ||
[[Betamethasone dipropionate]] was evaluated for effects when orally administered to pregnant rats from gestation day 6 through day 20 postpartum at dosages of 0, 100, 300, and 1000 mcg/kg/day. Mean maternal body weight was significantly reduced on gestation day 20 in animals dosed at 300 and 1000 mcg/kg/day. The mean duration of gestation was slightly, but statistically significantly, increased at 100, 300, and 1000 mcg/kg/day. The mean percentage of pups that survived to day 4 was reduced in relation to dosage. On lactation day 5, the percentage of pups with a reflex to right themselves when placed on their back was significantly reduced at 1000 mcg/kg/day. No effects on the ability of pups to learn were observed, and the ability of the offspring of treated rats to reproduce was not affected. | |||
Instruct the patient not to use | |useInNursing=Systemically administered [[corticosteroids]] appear in human milk and can suppress growth, interfere with [[endogenous]] [[corticosteroid]] production, or cause other untoward effects. It is not known whether topically administered [[calcipotriene]] or [[corticosteroids]] could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when [[calcipotriene]] and [[betamethasone dipropionate]] is administered to a nursing woman. Instruct the patient not to use [[calcipotriene]] and [[betamethasone dipropionate]] on the breast when nursing. | ||
|useInPed=Safety and effectiveness of the use of | |useInPed=Safety and effectiveness of the use of [[calcipotriene]] and [[betamethasone dipropionate]] in pediatric patients have not been studied. Because of a higher ratio of skin surface area to body mass, children under the age of 12 years are at particular risk of systemic adverse effects when they are treated with topical [[corticosteroids]]. They are, therefore, also at greater risk of [[HPA axis]] suppression and adrenal insufficiency with the use of topical [[corticosteroids]]. | ||
Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients treated with topical corticosteroids. | [[Cushing’s syndrome]], linear [[growth retardation]], delayed [[weight gain]], and [[Intracranial pressure|intracranial hypertension]] have been reported in pediatric patients treated with topical [[corticosteroids]]. | ||
Local adverse reactions including striae have been reported with use of topical corticosteroids in pediatric patients. | Local adverse reactions including [[striae]] have been reported with use of topical [[corticosteroids]] in pediatric patients. | ||
|useInGeri=Of the total number of subjects in the controlled clinical studies of | |useInGeri=Of the total number of subjects in the controlled clinical studies of [[calcipotriene]] and [[betamethasone dipropionate]] in [[psoriasis|plaque psoriasis]], 97 were 65 years or older, while 21 were 75 years or older. | ||
No overall differences in safety or effectiveness of | No overall differences in safety or effectiveness of [[calcipotriene]] and [[betamethasone dipropionate]] were observed between subjects in these subjects versus younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. | ||
|administration=Instruct patients to shake can prior to using | |administration=Instruct patients to shake can prior to using [[calcipotriene]] and [[betamethasone dipropionate]] and to wash their hands after applying the product. [[Calcipotriene]] and [[betamethasone dipropionate]] should not be used with [[occlusive dressing|occlusive dressings]] unless directed by a physician. [[Calcipotriene]] and [[betamethasone dipropionate]] is not for oral, ophthalmic, or intravaginal use. Avoid use on the face, [[groin]], or [[axillae]], or if skin atrophy is present at the treatment site. | ||
|drugBox=[[File:Calcipotriene drugbox.JPG|thumb|none|400px]] | |drugBox=[[File:Calcipotriene drugbox.JPG|thumb|none|400px]] | ||
[[File:Betamethasone dipropionate | [[File:Betamethasone dipropionate.JPG|thumb|none|400px]] | ||
|mechAction= | |mechAction=[[Calcipotriene]] and [[betamethasone dipropionate]] combines the pharmacological effects of [[calcipotriene]] hydrate as a synthetic [[vitamin D3]] analog and [[betamethasone dipropionate]] as a synthetic [[corticosteroid]]. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in [[psoriasis|plaque psoriasis]] are unknown. | ||
|structure= | |structure=[[Calcipotriene]] and [[betamethasone dipropionate]] contains [[calcipotriene]] hydrate and [[betamethasone dipropionate]]. It is intended for topical use only. | ||
Calcipotriene hydrate is a synthetic vitamin D3 analog. | [[Calcipotriene]] hydrate is a synthetic [[vitamin D3]] analog. | ||
Chemically, calcipotriene hydrate is 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol,24-cyclo-propyl-,monohydrate, (1α,3ß,5Z,7E,22E,24S) with the empirical formula C27H40O3,H20, a molecular weight of 430.6, and the following structural formula: | Chemically, [[calcipotriene]] hydrate is 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol,24-cyclo-propyl-,monohydrate, (1α,3ß,5Z,7E,22E,24S) with the empirical formula C27H40O3,H20, a molecular weight of 430.6, and the following structural formula: | ||
[[File:Calcipotriene and betamethasone dipropionate structure1.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | [[File:Calcipotriene and betamethasone dipropionate structure1.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | ||
Calcipotriene hydrate is a white to almost white, crystalline compound. | [[Calcipotriene]] hydrate is a white to almost white, crystalline compound. | ||
Betamethasone dipropionate is a synthetic corticosteroid. | [[Betamethasone dipropionate]] is a synthetic [[corticosteroid]]. | ||
Betamethasone dipropionate has the chemical name pregna-1,4-diene-3,20-dione-9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxypropoxy)-(11β,16β), with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula: | [[Betamethasone dipropionate]] has the chemical name pregna-1,4-diene-3,20-dione-9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxypropoxy)-(11β,16β), with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula: | ||
[[File:Calcipotriene and betamethasone dipropionate structure2.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | [[File:Calcipotriene and betamethasone dipropionate structure2.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | ||
|PD=Effects on Calcium Metabolism: | |PD=Effects on [[calcium metabolism|Calcium Metabolism]]: | ||
Effects of once daily application of | |||
Effects of once daily application of [[calcipotriene]] and [[betamethasone dipropionate]] for 4 weeks on [[calcium metabolism]] in adult subjects (N=564) with [[psoriasis|plaque psoriasis]] were examined in three randomized, multicenter, prospective vehicle- and/or active-controlled clinical trials. Following once daily application of [[calcipotriene]] and [[betamethasone dipropionate]], elevated serum [[calcium]] levels outside the normal range were observed in 3 subjects. Elevated urinary [[calcium]] levels outside the normal range were observed in 17 subjects. | |||
|PK='''Absorption''' | |PK='''Absorption''' | ||
The pharmacokinetics (PK) of | The pharmacokinetics (PK) of [[calcipotriene]] and [[betamethasone dipropionate]] was investigated in adult subjects (N = 35) with moderate to severe [[psoriasis|plaque psoriasis]] with a mean body surface area involvement of 17.5% and mean scalp involvement of 50.2%. Plasma concentrations of [[calcipotriene]] and [[betamethasone dipropionate]] and their main [[metabolites]] were measured after 4 weeks of once daily application of [[calcipotriene]] and [[betamethasone dipropionate]]. Following application of a mean ± SD total weekly dose of 61.8 ± 27.7 grams of [[calcipotriene]] and [[betamethasone dipropionate]], [[calcipotriene]] was quantifiable in 1 of 35 (2.9%) subjects and its main [[metabolite]], MC1080, in 3 of 35 (8.6%) subjects. For subjects with measurable concentrations, the maximal plasma concentrations ([[Cmax]]) and [[AUC|area under the concentration curve]] until the last measured time point (AUClast) for [[calcipotriene]] were 55.9 pg/mL and 82.5 pg*h/mL, respectively;and the mean ± SD [[Cmax]] and [[AUC|AUClast]] for MC1080 was 24.4 ± 1.9 pg/mL and 59.3 ± 5.4 pg*h/mL, respectively. [[Betamethasone dipropionate]] was quantifiable in 5 of 35 (14.3%) subjects and its main [[metabolite]], betamethasone 17-propionate (B17P), was quantifiable in 27 of 35 (77.1%) subjects. The mean ± SD [[Cmax]] and [[AUC|AUClast]] for [[betamethasone dipropionate]] were 52.2 ± 19.7 pg/mL and 36.5 ± 27.4 pg*h/mL, respectively and for B17P were 147.9 ± 224.0 pg/mL and 683.6 ± 910.6 pg*h/mL, respectively. The clinical significance of these findings is unknown. | ||
'''Metabolism''' | '''[[Metabolism]]''' | ||
Calcipotriene metabolism following systemic uptake is rapid and occurs in the liver. The primary metabolites of calcipotriene are less potent than the parent compound. | [[Calcipotriene]]: | ||
Calcipotriene is metabolized to MC1046 (the α,ß-unsaturated ketone analog of calcipotriene),which is metabolized further to MC1080 (a saturated ketone analog). MC1080 is the main metabolite in plasma. MC1080 is slowly metabolized to calcitroic acid. | [[Calcipotriene]] [[metabolism]] following systemic uptake is rapid and occurs in the [[liver]]. The primary [[metabolites]] of [[calcipotriene]] are less potent than the parent compound. | ||
[[Calcipotriene]] is metabolized to MC1046 (the α,ß-unsaturated [[ketone]] analog of [[calcipotriene]]),which is metabolized further to MC1080 (a saturated [[ketone]] analog). MC1080 is the main [[metabolite]] in plasma. MC1080 is slowly metabolized to [[calcitroic acid]]. | |||
Betamethasone dipropionate: | [[Betamethasone dipropionate]]: | ||
Betamethasone dipropionate is metabolized to betamethasone 17-propionate (B17P) and betamethasone, including the 6ß-hydroxy derivatives of those compounds by hydrolysis. B17P is the primary metabolite. | [[Betamethasone dipropionate]] is metabolized to betamethasone 17-propionate (B17P) and betamethasone, including the 6ß-hydroxy derivatives of those compounds by [[hydrolysis]]. B17P is the primary [[metabolite]]. | ||
|nonClinToxic='''[[Carcinogenesis]], [[Mutagenesis]], Impairment of [[Fertility]]''' | |nonClinToxic='''[[Carcinogenesis]], [[Mutagenesis]], Impairment of [[Fertility]]''' | ||
In a study in which albino hairless mice were exposed to both ultraviolet radiation (UVR) and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors. | When [[calcipotriene]] was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m2/day), no significant changes in [[tumor]] incidence were observed when compared to control. | ||
In a study in which albino hairless mice were exposed to both [[ultraviolet radiation]] (UVR) and topically applied [[calcipotriene]], a reduction in the time required for [[ultraviolet radiation|UVR]] to induce the formation of [[skin]] [[tumor|tumors]] was observed (statistically significant in males only), suggesting that [[calcipotriene]] may enhance the effect of [[ultraviolet radiation|UVR]] to induce [[skin]] [[tumor|tumors]]. | |||
A 104-week oral [[carcinogenicity]] study was conducted with [[calcipotriene]] in male and female rats at doses of 1, 5 and 15 mcg/kg/day (corresponding to dosages of approximately 6, 30, and 90 mcg/m2/day). Beginning week 71, the dosage for high-dose animals of both genders was reduced to 10 mcg/kg/day (corresponding to a dosage of approximately 60 mcg/m2/day). A treatment-related increase in [[benign]] C-cell [[adenoma|adenomas]] was observed in the [[thyroid]] of females that received 15 mcg/kg/day. A treatment-related increase in [[benign]] pheochromocytomas was observed in the [[adrenal glands]] of males receiving 15 mcg/kg/day. No other statistically significant differences in [[tumor]] incidence were observed when compared to control. The relevance of these findings to patients is unknown. | |||
When [[betamethasone dipropionate]] was applied topically to CD-1 mice for up to 24 months at dosages approximating 1.3, 4.2 and 8.5 mcg/kg/day in females, and 1.3, 4.2, and 12.9 mcg/kg/day in males (corresponding to dosages of up to approximately 26 mcg/m2/day and 39 mcg/m2/day, in females and males, respectively), no significant changes in [[tumor]] incidence were observed when compared to control. | |||
When [[betamethasone dipropionate]] was administered via oral gavage to male and female Sprague Dawley rats for up to 24 months at dosages of 20, 60, and 200 mcg/kg/day (corresponding to dosages of approximately 120, 360, and 1200 mcg/m2/day), no significant changes in [[tumor]] incidence were observed when compared to control. | |||
[[Calcipotriene]] did not elicit any genotoxic effects in the [[Ames test|Ames mutagenicity assay]], the mouse [[lymphoma]] TK locus assay, the human [[lymphocyte]] [[chromosome]] aberration test, or the mouse [[micronucleus]] test. | |||
[[Betamethasone dipropionate]] did not elicit any genotoxic effects in the [[Ames test|Ames mutagenicity assay]], the mouse [[lymphoma]] TK locus assay, or in the rat [[micronucleus]] test. | |||
Studies in rats with oral doses of up to 54 mcg/kg/day (324 mcg/m2/day) of [[calcipotriene]] indicated no impairment of fertility or general reproductive performance. | |||
Studies in male rats at oral doses of up to 200 mcg/kg/day (1200 mcg/m2/day), and in female rats at oral doses of up to 1000 mcg/kg/day (6000 mcg/m2/day), of [[betamethasone dipropionate]] indicated no impairment of [[fertility]]. | |||
|clinicalStudies=Two multicenter, randomized, double-blind trials were conducted in subjects with [[psoriasis|plaque psoriasis]]. In Trial One, 302 subjects were randomized to 1 of 3 treatment groups: [[calcipotriene]] and [[betamethasone dipropionate]], [[betamethasone dipropionate]] in the same vehicle, or [[calcipotriene]] hydrate in the same vehicle. In Trial Two, 426 subjects were randomized to 1 of 2 treatment groups: [[calcipotriene]] and [[betamethasone dipropionate]] or the vehicle alone. Baseline disease severity was graded using a 5-point Investigator’s Global Assessment (IGA). At baseline subjects scored “Mild”, “Moderate”, or “Severe”. The majority of subjects in both trials (76% and 75%) had disease of “Moderate” severity at baseline, 14% and 15% of subjects had disease of “Mild” severity at baseline and 10% of subjects had “Severe” disease at baseline in both trials. The extent of disease involvement assessed by mean body surface area was 7.1% (range 2 to 28%) and 7.5% (range 2 to 30%). In both trials, subjects were treated once daily for up to 4 weeks. | |||
Efficacy was assessed with treatment success defined as the proportion of subjects at Week 4 who were “Clear” or “Almost Clear” according to the IGA. Subjects with “Mild” disease at baseline were required to be “Clear” to be considered a treatment success. Table 1 presents the efficacy results for these trials. | |||
[[File:Calcipotriene and betamethasone dipropionate T1.JPG|thumb|none|400px|This image is provided by the National Library of Medicine]] | |||
|howSupplied=[[Calcipotriene]] and [[betamethasone dipropionate]] is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants. | |||
[[Calcipotriene]] and [[betamethasone dipropionate]] is available in aluminum cans of: | |||
|alcohol=Alcohol-Calcipotriene and betamethasone dipropionate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | *1 x 60 g (NDC 50222-302-60) | ||
*2 x 60 g (NDC 50222-302-66) | |||
|storage=Store [[calcipotriene]] and [[betamethasone dipropionate]] at 20°- 25°C (68° -77°F); excursions permitted between 15°-30°C (59°-86°F). | |||
*Contents under pressure. Do not puncture or incinerate. | |||
*Do not expose to heat or store at temperatures above 120°F (49°C). | |||
*Do not freeze. | |||
*The product should be used within six months after it has been opened. | |||
|packLabel=[[File:Calcipotriene and betamethasone dipropionate Ingredients1.JPG|thumb|none|400px|This image is provided by the National Library of Medicine]] | |||
[[File:Calcipotriene and betamethasone dipropionate Label1.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | |||
[[File:Calcipotriene and betamethasone dipropionate Label2.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | |||
[[File:Calcipotriene and betamethasone dipropionate Label3.jpg|thumb|none|400px|This image is provided by the National Library of Medicine]] | |||
|fdaPatientInfo=Advise the patient to read the FDA-approved patient labeling. | |||
Inform patients of the following: | |||
*Instruct patients to shake before use. | |||
*Instruct patients not to use more than 60 g every 4 days. | |||
*Discontinue therapy when control is achieved unless directed otherwise by the physician. | |||
*Avoid use of [[calcipotriene]] and [[betamethasone dipropionate]] on the face, underarms, groin or eyes. If this medicine gets on face or in mouth or eyes, wash area right away. | |||
*Wash hands after application. | |||
*Do not occlude the treatment area with a bandage or other covering unless directed by the physician. Instruct the patients not to use other products containing [[calcipotriene]] or a [[corticosteroid]] with [[calcipotriene]] and [[betamethasone dipropionate]] without first talking to the physician. | |||
*Instruct patients who use [[calcipotriene]] and [[betamethasone dipropionate]] to avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of [[phototherapy]] in patients who use [[calcipotriene]] and [[betamethasone dipropionate]]. | |||
*[[calcipotriene]] and [[betamethasone dipropionate]] is flammable; avoid heat, flame, or smoking when applying this medication. | |||
*The foam can be sprayed holding the can in any orientation except horizontally. | |||
|alcohol=Alcohol-[[Calcipotriene]] and [[betamethasone dipropionate]] interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |||
|brandNames=Enstilar® Foam | |||
}} | }} | ||
Latest revision as of 17:08, 25 July 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Allison Tu [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Calcipotriene and betamethasone dipropionate is a combination of a vitamin D analog and a corticosteroid that is FDA approved for the treatment of plaque psoriasis in patients 18 years of age and older. Common adverse reactions include tingling of skin, burning sensation, stinging sensation, and skin rash.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Calcipotriene and betamethasone dipropionate is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
Dosing Information
- Apply calcipotriene and betamethasone dipropionate to affected areas once daily for up to 4 weeks. Rub in calcipotriene and betamethasone dipropionate gently. Discontinue use when control is achieved.
- Instruct patients not to use more than 60 g every 4 days.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Calcipotriene and betamethasone dipropionate in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Calcipotriene and betamethasone dipropionate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Calcipotriene and betamethasone dipropionate FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Calcipotriene and betamethasone dipropionate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Calcipotriene and betamethasone dipropionate in pediatric patients.
Contraindications
There is limited information regarding Calcipotriene and betamethasone dipropionate Contraindications in the drug label.
Warnings
- Flammability
- The propellants in calcipotriene and betamethasone dipropionate are flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application.
- Hypercalcemia and Hypercalciuria
- Hypercalcemia and hypercalciuria have been observed with use of calcipotriene and betamethasone dipropionate. If hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized.
- The incidence of hypercalcemia and hypercalciuria following calcipotriene and betamethasone dipropionate treatment of more than 4 weeks has not been evaluated.
- Effects on Endocrine System
- Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Factors that predispose a patient to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test.
- If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid.
- Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria.
- Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios.
- Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure.
- Allergic Contact Dermatitis
- Allergic contact dermatitis has been observed with topical calcipotriene and topical corticosteroids. Allergic contact dermatitis to a topical corticosteroid is usually diagnosed by observing a failure to heal rather than a clinical exacerbation. Corroborate such an observation with appropriate diagnostic patch testing.
- Risks of Ultraviolet Light Exposures
- Patients who apply calcipotriene and betamethasone dipropionate to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc.
- Physicians may wish to limit or avoid use of phototherapy in patients who use calcipotriene and betamethasone dipropionate.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The rates of adverse reactions given below were derived from three randomized, multicenter, prospective vehicle and/or active-controlled clinical trials in subjects with plaque psoriasis. Subjects applied study product once daily for 4 weeks, and the median weekly dose of calcipotriene and betamethasone dipropionate was 24.8 g.
Adverse reactions reported in <1% of subjects treated with calcipotriene and betamethasone dipropionate included: application site irritation, application site pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, and exacerbation of psoriasis.
Postmarketing Experience
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Postmarketing reports for local adverse reactions to topical steroids include atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection and miliaria.
Drug Interactions
There is limited information regarding Calcipotriene and betamethasone dipropionate Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C There are no adequate and well-controlled studies in pregnant women. Pregnant women were excluded from the clinical studies conducted with calcipotriene and betamethasone dipropionate. calcipotriene and betamethasone dipropionate should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. Animal reproduction studies have not been conducted with calcipotriene and betamethasone dipropionate. Calcipotriene and betamethasone dipropionate contains calcipotriene that has been shown to be fetotoxic and betamethasone dipropionate that has been shown to be teratogenic in animals when given systemically.
Teratogenicity studies with calcipotriene were performed by the oral route in rats and rabbits. In rabbits, increased maternal and fetal toxicity were noted at a dosage of 12 mcg/kg/day (144 mcg/m2/day); a dosage of 36 mcg/kg/day (432 mcg/m2/day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (324 mcg/m2/day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles were most likely due to the effect of calcipotriene upon calcium metabolism. The estimated maternal and fetal no-adverse effect levels (NOAEL) in the rat (108 mcg/m2/day) and rabbit (48 mcg/m2/day) derived from oral studies are lower than the estimated maximum topical dose of calcipotriene in man (460 mcg/m2/day).
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
Betamethasone dipropionate has been shown to be teratogenic in mice and rabbits when given by the subcutaneous route at dosages of 156 mcg/kg/day (468 mcg/m2/day) and 2.5 mcg/kg/day (30 mcg/m2/day), respectively. Those dose levels are lower than the estimated maximum topical dose in man (about 5,950 mcg/m2/day). The abnormalities observed included umbilical hernia, exencephaly, and cleft palate.
Two oral peri- and post-natal development studies were conducted with rats:
Pregnant Wistar rats were dosed daily with calcipotriene at exposures of 0, 6, 18 or 54 mcg/kg/day from gestation day 15 through day 20 postpartum. No remarkable effects were observed on any parameter, including survival, behavior, body weight, litter parameters, or the ability to nurse or rear pups.
Betamethasone dipropionate was evaluated for effects when orally administered to pregnant rats from gestation day 6 through day 20 postpartum at dosages of 0, 100, 300, and 1000 mcg/kg/day. Mean maternal body weight was significantly reduced on gestation day 20 in animals dosed at 300 and 1000 mcg/kg/day. The mean duration of gestation was slightly, but statistically significantly, increased at 100, 300, and 1000 mcg/kg/day. The mean percentage of pups that survived to day 4 was reduced in relation to dosage. On lactation day 5, the percentage of pups with a reflex to right themselves when placed on their back was significantly reduced at 1000 mcg/kg/day. No effects on the ability of pups to learn were observed, and the ability of the offspring of treated rats to reproduce was not affected.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Calcipotriene and betamethasone dipropionate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Calcipotriene and betamethasone dipropionate during labor and delivery.
Nursing Mothers
Systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topically administered calcipotriene or corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when calcipotriene and betamethasone dipropionate is administered to a nursing woman. Instruct the patient not to use calcipotriene and betamethasone dipropionate on the breast when nursing.
Pediatric Use
Safety and effectiveness of the use of calcipotriene and betamethasone dipropionate in pediatric patients have not been studied. Because of a higher ratio of skin surface area to body mass, children under the age of 12 years are at particular risk of systemic adverse effects when they are treated with topical corticosteroids. They are, therefore, also at greater risk of HPA axis suppression and adrenal insufficiency with the use of topical corticosteroids.
Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients treated with topical corticosteroids.
Local adverse reactions including striae have been reported with use of topical corticosteroids in pediatric patients.
Geriatic Use
Of the total number of subjects in the controlled clinical studies of calcipotriene and betamethasone dipropionate in plaque psoriasis, 97 were 65 years or older, while 21 were 75 years or older.
No overall differences in safety or effectiveness of calcipotriene and betamethasone dipropionate were observed between subjects in these subjects versus younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Gender
There is no FDA guidance on the use of Calcipotriene and betamethasone dipropionate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Calcipotriene and betamethasone dipropionate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Calcipotriene and betamethasone dipropionate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Calcipotriene and betamethasone dipropionate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Calcipotriene and betamethasone dipropionate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Calcipotriene and betamethasone dipropionate in patients who are immunocompromised.
Administration and Monitoring
Administration
Instruct patients to shake can prior to using calcipotriene and betamethasone dipropionate and to wash their hands after applying the product. Calcipotriene and betamethasone dipropionate should not be used with occlusive dressings unless directed by a physician. Calcipotriene and betamethasone dipropionate is not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Monitoring
There is limited information regarding Calcipotriene and betamethasone dipropionate Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Calcipotriene and betamethasone dipropionate and IV administrations.
Overdosage
There is limited information regarding Calcipotriene and betamethasone dipropionate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Mechanism of Action
Calcipotriene and betamethasone dipropionate combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.
Structure
Calcipotriene and betamethasone dipropionate contains calcipotriene hydrate and betamethasone dipropionate. It is intended for topical use only.
Calcipotriene hydrate is a synthetic vitamin D3 analog.
Chemically, calcipotriene hydrate is 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol,24-cyclo-propyl-,monohydrate, (1α,3ß,5Z,7E,22E,24S) with the empirical formula C27H40O3,H20, a molecular weight of 430.6, and the following structural formula:
Calcipotriene hydrate is a white to almost white, crystalline compound.
Betamethasone dipropionate is a synthetic corticosteroid.
Betamethasone dipropionate has the chemical name pregna-1,4-diene-3,20-dione-9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxypropoxy)-(11β,16β), with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula:
Pharmacodynamics
Effects on Calcium Metabolism:
Effects of once daily application of calcipotriene and betamethasone dipropionate for 4 weeks on calcium metabolism in adult subjects (N=564) with plaque psoriasis were examined in three randomized, multicenter, prospective vehicle- and/or active-controlled clinical trials. Following once daily application of calcipotriene and betamethasone dipropionate, elevated serum calcium levels outside the normal range were observed in 3 subjects. Elevated urinary calcium levels outside the normal range were observed in 17 subjects.
Pharmacokinetics
Absorption
The pharmacokinetics (PK) of calcipotriene and betamethasone dipropionate was investigated in adult subjects (N = 35) with moderate to severe plaque psoriasis with a mean body surface area involvement of 17.5% and mean scalp involvement of 50.2%. Plasma concentrations of calcipotriene and betamethasone dipropionate and their main metabolites were measured after 4 weeks of once daily application of calcipotriene and betamethasone dipropionate. Following application of a mean ± SD total weekly dose of 61.8 ± 27.7 grams of calcipotriene and betamethasone dipropionate, calcipotriene was quantifiable in 1 of 35 (2.9%) subjects and its main metabolite, MC1080, in 3 of 35 (8.6%) subjects. For subjects with measurable concentrations, the maximal plasma concentrations (Cmax) and area under the concentration curve until the last measured time point (AUClast) for calcipotriene were 55.9 pg/mL and 82.5 pg*h/mL, respectively;and the mean ± SD Cmax and AUClast for MC1080 was 24.4 ± 1.9 pg/mL and 59.3 ± 5.4 pg*h/mL, respectively. Betamethasone dipropionate was quantifiable in 5 of 35 (14.3%) subjects and its main metabolite, betamethasone 17-propionate (B17P), was quantifiable in 27 of 35 (77.1%) subjects. The mean ± SD Cmax and AUClast for betamethasone dipropionate were 52.2 ± 19.7 pg/mL and 36.5 ± 27.4 pg*h/mL, respectively and for B17P were 147.9 ± 224.0 pg/mL and 683.6 ± 910.6 pg*h/mL, respectively. The clinical significance of these findings is unknown.
Calcipotriene: Calcipotriene metabolism following systemic uptake is rapid and occurs in the liver. The primary metabolites of calcipotriene are less potent than the parent compound. Calcipotriene is metabolized to MC1046 (the α,ß-unsaturated ketone analog of calcipotriene),which is metabolized further to MC1080 (a saturated ketone analog). MC1080 is the main metabolite in plasma. MC1080 is slowly metabolized to calcitroic acid.
Betamethasone dipropionate: Betamethasone dipropionate is metabolized to betamethasone 17-propionate (B17P) and betamethasone, including the 6ß-hydroxy derivatives of those compounds by hydrolysis. B17P is the primary metabolite.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m2/day), no significant changes in tumor incidence were observed when compared to control.
In a study in which albino hairless mice were exposed to both ultraviolet radiation (UVR) and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors.
A 104-week oral carcinogenicity study was conducted with calcipotriene in male and female rats at doses of 1, 5 and 15 mcg/kg/day (corresponding to dosages of approximately 6, 30, and 90 mcg/m2/day). Beginning week 71, the dosage for high-dose animals of both genders was reduced to 10 mcg/kg/day (corresponding to a dosage of approximately 60 mcg/m2/day). A treatment-related increase in benign C-cell adenomas was observed in the thyroid of females that received 15 mcg/kg/day. A treatment-related increase in benign pheochromocytomas was observed in the adrenal glands of males receiving 15 mcg/kg/day. No other statistically significant differences in tumor incidence were observed when compared to control. The relevance of these findings to patients is unknown.
When betamethasone dipropionate was applied topically to CD-1 mice for up to 24 months at dosages approximating 1.3, 4.2 and 8.5 mcg/kg/day in females, and 1.3, 4.2, and 12.9 mcg/kg/day in males (corresponding to dosages of up to approximately 26 mcg/m2/day and 39 mcg/m2/day, in females and males, respectively), no significant changes in tumor incidence were observed when compared to control.
When betamethasone dipropionate was administered via oral gavage to male and female Sprague Dawley rats for up to 24 months at dosages of 20, 60, and 200 mcg/kg/day (corresponding to dosages of approximately 120, 360, and 1200 mcg/m2/day), no significant changes in tumor incidence were observed when compared to control.
Calcipotriene did not elicit any genotoxic effects in the Ames mutagenicity assay, the mouse lymphoma TK locus assay, the human lymphocyte chromosome aberration test, or the mouse micronucleus test.
Betamethasone dipropionate did not elicit any genotoxic effects in the Ames mutagenicity assay, the mouse lymphoma TK locus assay, or in the rat micronucleus test.
Studies in rats with oral doses of up to 54 mcg/kg/day (324 mcg/m2/day) of calcipotriene indicated no impairment of fertility or general reproductive performance.
Studies in male rats at oral doses of up to 200 mcg/kg/day (1200 mcg/m2/day), and in female rats at oral doses of up to 1000 mcg/kg/day (6000 mcg/m2/day), of betamethasone dipropionate indicated no impairment of fertility.
Clinical Studies
Two multicenter, randomized, double-blind trials were conducted in subjects with plaque psoriasis. In Trial One, 302 subjects were randomized to 1 of 3 treatment groups: calcipotriene and betamethasone dipropionate, betamethasone dipropionate in the same vehicle, or calcipotriene hydrate in the same vehicle. In Trial Two, 426 subjects were randomized to 1 of 2 treatment groups: calcipotriene and betamethasone dipropionate or the vehicle alone. Baseline disease severity was graded using a 5-point Investigator’s Global Assessment (IGA). At baseline subjects scored “Mild”, “Moderate”, or “Severe”. The majority of subjects in both trials (76% and 75%) had disease of “Moderate” severity at baseline, 14% and 15% of subjects had disease of “Mild” severity at baseline and 10% of subjects had “Severe” disease at baseline in both trials. The extent of disease involvement assessed by mean body surface area was 7.1% (range 2 to 28%) and 7.5% (range 2 to 30%). In both trials, subjects were treated once daily for up to 4 weeks.
Efficacy was assessed with treatment success defined as the proportion of subjects at Week 4 who were “Clear” or “Almost Clear” according to the IGA. Subjects with “Mild” disease at baseline were required to be “Clear” to be considered a treatment success. Table 1 presents the efficacy results for these trials.
How Supplied
Calcipotriene and betamethasone dipropionate is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants.
Calcipotriene and betamethasone dipropionate is available in aluminum cans of:
- 1 x 60 g (NDC 50222-302-60)
- 2 x 60 g (NDC 50222-302-66)
Storage
Store calcipotriene and betamethasone dipropionate at 20°- 25°C (68° -77°F); excursions permitted between 15°-30°C (59°-86°F).
- Contents under pressure. Do not puncture or incinerate.
- Do not expose to heat or store at temperatures above 120°F (49°C).
- Do not freeze.
- The product should be used within six months after it has been opened.
Images
Drug Images
{{#ask: Page Name::Calcipotriene and betamethasone dipropionate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Calcipotriene and betamethasone dipropionate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling. Inform patients of the following:
- Instruct patients to shake before use.
- Instruct patients not to use more than 60 g every 4 days.
- Discontinue therapy when control is achieved unless directed otherwise by the physician.
- Avoid use of calcipotriene and betamethasone dipropionate on the face, underarms, groin or eyes. If this medicine gets on face or in mouth or eyes, wash area right away.
- Wash hands after application.
- Do not occlude the treatment area with a bandage or other covering unless directed by the physician. Instruct the patients not to use other products containing calcipotriene or a corticosteroid with calcipotriene and betamethasone dipropionate without first talking to the physician.
- Instruct patients who use calcipotriene and betamethasone dipropionate to avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of phototherapy in patients who use calcipotriene and betamethasone dipropionate.
- calcipotriene and betamethasone dipropionate is flammable; avoid heat, flame, or smoking when applying this medication.
- The foam can be sprayed holding the can in any orientation except horizontally.
Precautions with Alcohol
Alcohol-Calcipotriene and betamethasone dipropionate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Enstilar® Foam
Look-Alike Drug Names
There is limited information regarding Calcipotriene and betamethasone dipropionate Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.